C-reactive protein as a risk factor versus risk marker

Current Opinion in Lipidology

Volumn 15, Issue 6, 2004, Pages 651-657

  De Maat, Moniek P M ^a   Trion, Astrid ^b,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; C reactive protein; Cardiovascular disease; Inflammation; Thrombosis

Indexed keywords

C REACTIVE PROTEIN;

ATHEROSCLEROSIS; BLOOD LEVEL; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; GENETICS; HUMAN; INFLAMMATION; META ANALYSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; THROMBOSIS; TRANSGENIC ANIMAL;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CORONARY ARTERIOSCLEROSIS; CORONARY DISEASE; ENDOTHELIAL CELLS; HUMANS; MONOCYTES; RISK FACTORS;

ANIMALIA;

EID: 10044271084     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200412000-00005     Document Type: Review

References (64)

1. Ross R. Mechanisms of disease - atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340:115-126.
2. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 2004; 116 (Suppl 6A):9S-16S.
3. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, c-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. J Am Med Assoc 1998; 279:1477-1482.
4. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350:1387-1397. An updated meta-analysis involving a total of 7068 patients with coronary heart disease shows an odds ratio of 1.58 (95% confidence interval, 1.48-1.68).
5. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999; 138:3419-3420.
6. Haverkate F, Thompson SG, Pyke SD, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349:462-466.
7. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103:1813-1818.
8. Pepys MB. C-reactive protein fifty years on. Lancet 1981; 1:653-657.
9. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107:499-511.
10. Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004; 109:1349-1353.
11. Grander W, Dichtl W, Prokop W, et al. C-reactive protein plasma levels but not factor VII activity predict clinical outcome in patients undergoing elective coronary intervention. Clin Cardiol 2004; 27:211-216.
12. Magadle R, Hertz I, Merlon H, et al. The relation between preprocedural C-reactive protein levels and early and late complications in patients with acute myocardial infarction undergoing interventional coronary angioplasty. Clin Cardiol 2004; 27:163-168.
13. Bakri RS, Afzali B, Covic A, et al. Cardiovascular disease in renal allograft recipients is associated with elevated sialic acid or markers of inflammation. Clin Transplant 2004; 18:201-204.
14. Schulze MB, Rimm EB, Li T, et al. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care 2004; 27:889-894.
15. Choi H, Cho DH, Shin HH, Park JB. Association of high sensitivity C-reactive protein with coronary heart disease prediction, but not with carotid atherosclerosis, in patients with hypertension. Circ J 2004; 68:297-303.
16. Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003; 108:2317-2322.
17. Lombardo A, Biasucci LM, Lanza GA, et al. Inflammation as a possible link between coronary and carotid plaque instability. Circulation 2004; 109:3158-3163. In patients with unstable angina and elevated CRP the carotid artery plaques are less stable, which may result in rapid plaque growth and atherosclerotic plaque instability.
18. -/- mice. These data suggest a causal, proatherogenic role for CRP in vivo.
19. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102:2165-2168.
20. Pasceri V, Cheng JS, Willerson JT, et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103:2531-2534.
21. Devaraj S, Kumaresan PR, Jialal I. Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. J Mol Cell Cardiol 2004; 36:405-410.
22. Verma S, Li SH, Badiwala MV, Weisel RD, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002; 105:1890-1896.
23. Nagoshi Y, Kuwasako K, Cao YN, et al. Effects of C-reactive protein on atherogenic mediators and adrenomedullin in human coronary artery endothelial and smooth muscle cells. Biochem Biophys Res Commun 2004; 314:1057-1063.
24. Venugopal SK, Devaraj S, Yuhanna I, et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002; 106:1439-1441.
25. Venugopal SK, Devaraj S, Jialal I. C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation 2003; 108:1676-1678.
26. Wang CH, Li SH, Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003; 107:1783-1790.
27. Torzewski J, Torzewski M, Bowyer DE, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998; 18:1386-1392.
28. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000; 20:2094-2099.
29. Han KH, Hong KH, Park JH, et al. C-reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation 2004; 109:2566-2571.
30. Wolbink GJ, Brouwer MC, Buysmann S, et al. CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. J Immunol 1996; 157:473-479.
31. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111:1805-1812.
32. Griselli M, Herbert J, Hutchinson WL, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999; 190:1733-1740.
33. Torzewski J, Bowyer DE, Waltenberger J, Fitzsimmons C. Processes in atherogenesis: complement activation. Atherosclerosis 1997; 132:131-138.
34. Li SH, Szmitko PE, Weisel RD, et al. C-reactive protein upregulates complement-inhibitory factors in endothelial cells. Circulation 2004; 109:833-836.
35. Szalai AJ, Agrawal A, Greenhough TJ, Volanakis JE. C-reactive protein: structural biology and host defense function. Clin Chem Lab Med 1999; 37:265-270.
36. Szalai AJ, Briles DE, Volanakis JE. Role of complement in C-reactive-protein-mediated protection of mice from Streptococcus pneumoniae. Infect Immun 1996; 64:4850-4853.
37. Bodman-Smith KB, Gregory RE, Harrison PT, Raynes JG. FcγRlla expression with FcγRI results in C-reactive protein- and IgG-mediated phagocytosis. J Leukoc Biol 2004; 75:1029-1035.
38. Bhakdi S, Torzewski M, Klouche M, Hemmes M. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 1999; 19:2348-2354.
39. Bhakdi S, Torzewski M, Paprotka K, et al. Possible protective role for C-reactive protein in atherogenesis: complement activation by modified lipoproteins halts before detrimental terminal sequence. Circulation 2004; 109:1870-1876.
40. Taskinen S, Kovanen PT, Jarva H, et al. Binding of C-reactive protein to modified low-density-lipoprotein particles: identification of cholesterol as a novel ligand for C-reactive protein. Biochem J 2002; 367:403-412.
41. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A 2002; 99:13043-13048.
42. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001; 103:1194-1197.
43. Wadham C, Albanese N, Roberts J, et al. High-density lipoproteins neutralize C-reactive protein proinflammatory activity. Circulation 2004; 109:2116-2122.
44. Nakagomi A, Freedman SB, Geczy CL. Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment. Circulation 2000; 101:1785-1791.
45. Cermak J, Key NS, Bach RR, et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82:513-520.
46. Paffen E, Vos HL, Bertina RM. C-reactive protein does not directly induce tissue factor in human monocytes. Arterioscler Thromb Vasc Biol 2004; 24:975-981.
47. Danenberg HD, Szalai AJ, Swaminathan RV, et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 2003; 108:512-515. The prothrombotic effect of CRP was shown in CRP transgenic mice using a model of transluminal wire injury; in the CRP transgenic mice the femoral arteries were occluded more than in wild-type mice 28 days after the injury.
48. Blann AD, Lip GY. Effects of C-reactive protein on the release of von Willebrand factor, E-selectin, thrombomodulin and intercellular adhesion molecule-1 from human umbilical vein endothelial cells. Blood Coagul Fibrinolysis 2003; 14:335-340.
49. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003; 107:398-404.
50. Eren M, Painter CA, Atkinson JB, et al. Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation 2002; 106:491-496.
51. Verma S, Kuliszewski MA, Li SH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 2004; 109:2058-2067.
52. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibts angiogeness. Circulation 2002; 106:913-919.
53. Khreiss T, Jozsef L, Potempa LA, Filep JG. Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation 2004; 109:2016-2022. The loss of the cyclic pentameric structure of CRP, resulting in formation of modified or monomeric CRP, is a prerequisite for endothelial cell activation.
54. Diehl EE, Haines 3rd GK, Radosevich JA, Potempa LA. Immunohistochemical localization of modified C-reactive protein antigen in normal vascular tissue. Am J Med Sci 2000; 319:79-83.
55. Pankow JS, Folsom AR, Cushman M, 3rd. Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis 2001; 154:681-689.
56. Vickers MA, Green FR, Terry C, et al. Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc Res 2002; 53:1029-1034.
57. MacGregor AJ, Gallimore JR, Spector TD, Pepys MB. Genetic effects on baseline values of C-reactive protein and serum amyloid a protein: a comparison of monozygotic and dizygotic twins. Clin Chem 2004; 50:130-134.
58. Brull DJ, Serrano N, Zito F, et al. Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol 2003; 23:2063-2069.
59. Szalai AJ, McCrory MA, Cooper GS, et al. Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun 2002; 3:14-19.
60. Zee RY, Hegener HH, Cook NR, Ridker PM. C-reactive protein gene polymorphism and the risk of venous thramboembolism: a haplotype-base analysis. J Thromb Haemost 2004; 2:1240-1243.
61. Zee RY, Ridker PM. Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis 2002; 162:217-219.
62. Russell AI, Cunninghame Graham DS, Shepherd C, et al. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 2004; 13:137-147.
63. Liuzzo G, Buffon A, Biasucci LM, et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation 1998; 98:2370-2376.
64. Verschuur M, van der Seek MT, Tak HS, et al. Interindividual variation in the response by fibrinogen, C-reactive protein and interleukin-6 to yellow fever vaccination. Blood Coagul Fibrinolysis 2004; 15:399-404.